I value being part of the largest and fastest growing user community of its kind in the world
Instem Client
LAB Research International To Deploy Provantis 7 in three Countries
Rapidly Growing CRO Switches to Provantis 7 with Over 300 Users at Sites in Canada, Hungary and Denmark
CONSHOHOCKEN, PA - Dec. 2, 2005 - - Instem, a leading global information solutions provider, today announced it is implementing a complete Provantis 7 system-project across three LAB Research International (LAB) sites.
"Provantis 7 by Instem was the only solution we seriously considered, it is clearly the gold standard," commented Leigh Berryman, President, LAB. "Provantis provides the functionality we need to streamline our processes giving a clear return on investment. As a global company, we needed an integrated global solution and Provantis 7 was that solution. We have also been delighted at the way it was quickly and widely embraced by our users due to its ease of use and integrated design."
Provantis is a modern, fully integrated Windows-based solution, which enables data to be shared across every discipline of a toxicology laboratory. It addresses all the needs of the toxicology laboratory from compound receipt through to final report production.
LAB's objective was to acquire a single integrated global system, which covered the areas of planning, protocol creation, data collection, data analysis, statistical evaluation and final report production for all toxicology studies it conducts.
LAB is deploying all ten Provantis modules, including Instem's unique resource-planning tool -TRP (Toxicology Resource Planning).
TRP is the only toxicology-focused resource planning solution in today's market that manages studies, people, equipment, animals and facilities for an organization to realize more study throughput and scientific up-time with less administration.
LAB sees TRP as a key component to their business, assisting them in responding quickly to a sponsor's request by instantaneously assessing across all sites the resources needed to complete a study.
"Provantis is by far the most prevalent solution in the industry and we will gain a stronger competitive position by quickly and comprehensively standardizing on the entire suite of modules at every LAB location," stated Denis Pilon, Chief Operating Officer at LAB in Montreal, Canada.
About Instem
Instem is a world-leading information solutions provider for the Life Sciences - accelerating drug and chemical development by increasing client productivity and enhancing the processes that lead to safer, more effective products.
Established in 1969, Instem has offices in the United States and Europe with its solutions supported in thirteen countries. Instem serves large multi-national corporations and smaller organizations in overcoming the challenges of managing information and provides solutions that help them further their missions while creating a competitive advantage. For more information on Instem and its solutions, please visit www.instem.com or contact them by email at info@instem.com.
About LAB International
LAB International (LAB Pharma and LAB Research) is an integrated drug development company. LAB Pharma is focused on the growing multi-billion dollar inhalation market. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN® dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, and growth hormone deficiencies. LAB Research is a profitable and growing pre-clinical contract research services division supporting its clients base from state-of-the-art facilities in Canada, the US, Denmark and Hungary. LAB Research currently employs over 400 professionals focused on providing high quality, competitively priced pre-clinical drug development services to the biopharmaceutical industry.
For more information about LAB Research and its services, please visit www.preclin.com or contact them by email at businessdevelopment@preclin.com
LAB's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "LAB", on the Frankfurt Regulated Unofficial Market under the symbol "LD9.F" and on XETRA under the symbol "LD9.DE" with 56.0 million shares outstanding. For further information visit LAB's website at www.labinc.ca.
Press Contact:
Gary E. Mitchell, VP Global Marketing, Instem US HQ
Tel: (610) 941-0990
Email: gary.mitchell@instem.com
All trademarks used are properties of their respective owners.
Links
Accessibility
Contact Us
© 2001 - 2011 Instem - All rights reserved